Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.
Matthew R. Smith, Shahneen Sandhu, William Kevin Kelly, Howard I. Scher, Eleni Efstathiou, Primo N. Lara, Evan Y. Yu, Daniel J. George, Kim N., Jason M. Summa, Nishi Kothari, Xin Zhao, Byron M. Espina, Deborah Ricci, Jason S. Simon, NamPhuong Tran, Karim Fizazi (2019). Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.. , 37(7_suppl), DOI: https://doi.org/10.1200/jco.2019.37.7_suppl.202.
